




VisionCare Backgrounder

VisionCare Ophthalmic Technologies, Inc., is a privately-held company focused on development, manufacturing, and marketing of implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. VisionCare's initial product (Implantable Miniature Telescope by Dr. Isaac Lipshitz) is a first-of-kind medical device for the most advanced form of AMD (End-Stage AMD) and the leading cause of irreversible blindness in developed countries. The device has been granted approval by the FDA and Israel's Ministry of Health, and has also received a CE Mark in Europe.

Over 20 million people in developed countries are estimated to have some form of AMD. The disease affects the central retina, or macula, which is responsible for detailed central vision that controls important functional visual activities such as reading, recognizing faces, and watching television. Despite recent AMD drug approvals, the number of people affected by advanced forms of AMD is expected to double by the year 2050 due to limitations in efficacy and the growing older population. According to the National Eye Institute, vision-impairing advanced forms of AMD ('wet' and *advanced 'dry'* AMD) affect approximately 2 million people in the U.S., and there are an additional 7 million individuals at risk of progressing to advanced AMD. Affected individuals are generally over 65 years of age. The high prevalence of AMD, in conjunction with limited treatment options, has created a major public health concern and an intense need for treatments that increase function and independence in this patient population.

There are currently no available medical treatments for dry AMD, and with efficacy limitations to AMD drugs, depending on how a patient's disease progresses, visual impairment eventually occurs. Ultimately, severe and untreatable vision loss affects both eyes in the End-Stage form of AMD, creating a central blind spot that impairs the patient's ability to read, provide care for him/herself or others, or even recognize family and friends. VisionCare's telescope implant is designed to improve outcomes by providing patients with End-Stage AMD the ability to regain central vision.



Implantable Telescope Technology

The telescope implant, about the size of a pea, is comprised of quartz glass micro-optics that render an enlarged central vision image onto the healthy retinal areas surrounding the degenerated macula. The device is implanted behind the iris (colored-portion) in one eye during an outpatient surgical procedure. This essentially converts the eye into a telephoto system that reduces the impact of the blind spot by a factor of the telescope's magnification (approximately 2.5X) within a relatively wide field of view. Additionally, more central field

visual information is available to viable retina photoreceptors. The new central vision image allows patients to recognize images that were previously difficult or impossible to see (e.g., see facial features, read street signs, watch TV).

Over 260 of the company's telescope implants have been used in clinical trials that have generated extensive long-term safety and efficacy data. The pivotal IMT002 clinical trial, conducted across 28 leading U.S. ophthalmic centers, demonstrated the majority of patients gained at least 3 lines of visual acuity on the study eye chart and clinically meaningful quality-of-life improvements on the National Eye Institute Visual Function Questionnaire. Ten peer-reviewed publications discussing the clinical and scientific data have appeared in top-tier ophthalmic journals.

VisionCare is headquartered in Saratoga, CA, with research facilities in Petah Tikva, Israel.
www.visioncareinc.net